$286 Million is the total value of Ally Bridge Group (NY) LLC's 30 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 41.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NTRA | NATERA INC | $25,029,000 | -16.2% | 268,000 | 0.0% | 8.75% | -0.4% | |
| ARVN | Buy | ARVINAS INC | $18,892,000 | +9.5% | 230,000 | +9.5% | 6.60% | +30.1% |
| RGEN | REPLIGEN CORP | $18,539,000 | -8.4% | 70,000 | 0.0% | 6.48% | +8.9% | |
| New | ISOPLEXIS CORP | $16,267,000 | – | 1,770,118 | +100.0% | 5.68% | – | |
| FATE | FATE THERAPEUTICS INC | $15,798,000 | -1.3% | 270,000 | 0.0% | 5.52% | +17.3% | |
| COGT | Sell | COGENT BIOSCIENCES INC | $12,884,000 | -5.6% | 1,501,591 | -7.5% | 4.50% | +12.2% |
| MRTX | Sell | MIRATI THERAPEUTICS INC | $12,469,000 | -25.8% | 85,000 | -10.5% | 4.36% | -11.8% |
| VRDN | Sell | VIRIDIAN THERAPEUTICS INC | $11,956,000 | -19.7% | 604,774 | -33.2% | 4.18% | -4.5% |
| SYRS | Buy | SYROS PHARMACEUTICALS INC | $11,540,000 | -24.9% | 3,539,895 | +2.9% | 4.03% | -10.8% |
| SRPT | New | SAREPTA THERAPEUTICS INC | $10,806,000 | – | 120,000 | +100.0% | 3.78% | – |
| GH | New | GUARDANT HEALTH INC | $10,502,000 | – | 105,000 | +100.0% | 3.67% | – |
| NUVB | Sell | NUVATION BIO INC | $10,176,000 | -38.4% | 1,197,152 | -27.9% | 3.56% | -26.7% |
| IDYA | Sell | IDEAYA BIOSCIENCES INC | $10,165,000 | -30.8% | 430,000 | -25.3% | 3.55% | -17.7% |
| LNTH | New | LANTHEUS HLDGS INC | $9,534,000 | – | 330,000 | +100.0% | 3.33% | – |
| SOMALOGIC INC | $9,312,000 | -6.1% | 800,000 | 0.0% | 3.26% | +11.7% | ||
| ISEE | Buy | IVERIC BIO INC | $9,196,000 | +126.5% | 550,000 | +120.0% | 3.21% | +169.2% |
| NSTG | NANOSTRING TECHNOLOGIES INC | $7,813,000 | -12.0% | 185,000 | 0.0% | 2.73% | +4.6% | |
| IOVA | IOVANCE BIOTHERAPEUTICS INC | $7,769,000 | -22.6% | 406,986 | 0.0% | 2.72% | -8.0% | |
| NTLA | INTELLIA THERAPEUTICS INC | $7,686,000 | -11.9% | 65,000 | 0.0% | 2.69% | +4.8% | |
| NAUT | Sell | NAUTILUS BIOTECHNOLOGY INC | $6,346,000 | -31.1% | 1,225,060 | -18.3% | 2.22% | -18.1% |
| SIGHT SCIENCES INC | $6,014,000 | -22.6% | 342,304 | 0.0% | 2.10% | -8.0% | ||
| LPTX | Buy | LEAP THERAPEUTICS INC | $5,881,000 | +22.2% | 1,815,000 | +51.2% | 2.06% | +45.2% |
| GOSS | Sell | GOSSAMER BIO INC | $5,372,000 | -63.6% | 475,000 | -59.6% | 1.88% | -56.8% |
| JNCE | New | JOUNCE THERAPEUTICS INC | $4,801,000 | – | 575,000 | +100.0% | 1.68% | – |
| RAPID MICRO BIOSYSTEMS INC | $4,660,000 | -42.4% | 437,960 | 0.0% | 1.63% | -31.5% | ||
| STOK | New | STOKE THERAPEUTICS INC | $4,438,000 | – | 185,000 | +100.0% | 1.55% | – |
| MDVL | MEDAVAIL HOLDINGS INC | $4,089,000 | -52.1% | 2,920,780 | 0.0% | 1.43% | -43.0% | |
| VERV | Buy | VERVE THERAPEUTICS INC | $4,069,000 | +477.2% | 110,360 | +635.7% | 1.42% | +587.0% |
| CYT | CYTEIR THERAPEUTICS INC | $3,633,000 | -35.2% | 319,538 | 0.0% | 1.27% | -23.0% | |
| MGNX | Sell | MACROGENICS INC | $482,000 | -93.7% | 30,000 | -91.8% | 0.17% | -92.5% |
| BOLT | Exit | BOLT BIOTHERAPEUTICS INC | $0 | – | -257,267 | -100.0% | -0.96% | – |
| ACET | Exit | ADICET BIO INC | $0 | – | -425,000 | -100.0% | -0.98% | – |
| BLI | Exit | BERKELEY LTS INC | $0 | – | -201,996 | -100.0% | -1.16% | – |
| AMRS | Exit | AMYRIS INC | $0 | – | -352,445 | -100.0% | -1.42% | – |
| NVTA | Exit | INVITAE CORP | $0 | – | -199,900 | -100.0% | -1.67% | – |
| Exit | APELLIS PHARMACEUTICALS INCcall | $0 | – | -300,000 | -100.0% | -2.91% | – | |
| Exit | SPDR SER TRput | $0 | – | -200,000 | -100.0% | -7.39% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Fan Yu #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MEDAVAIL HOLDINGS INC | 11 | Q2 2023 | 8.9% |
| UNUM THERAPEUTICS INC | 8 | Q3 2022 | 7.3% |
| RAPID MICRO BIOSYSTEMS INC-A | 8 | Q2 2023 | 3.5% |
| FATE THERAPEUTICS INC | 7 | Q2 2022 | 5.8% |
| VIRIDIAN THERAPEUTICS INC | 7 | Q2 2023 | 6.8% |
| SYROS PHARMACEUTICALS INC | 7 | Q2 2022 | 4.9% |
| REPLIGEN CORP | 7 | Q4 2022 | 6.5% |
| NAUTILUS BIOTECHNOLOGY INC | 7 | Q4 2022 | 3.8% |
| ARVINAS INC | 6 | Q1 2022 | 7.5% |
| NUVATION BIO INC | 6 | Q2 2022 | 4.9% |
View Ally Bridge Group (NY) LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cogent Biosciences, Inc. | November 19, 2020 | 1,420,500 | 8.0% |
View Ally Bridge Group (NY) LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-06-21 |
| 13F-HR | 2023-05-15 |
| 4 | 2023-03-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
View Ally Bridge Group (NY) LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.